FDMT Gross Profit from 2010 to 2024

FDMT Stock

USD 7.50 0.12 1.57%

4D Molecular Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit 4D Molecular Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2019-09-30

Previous Quarter

-1.6 M

Current Value

3 K

Quarterly Volatility

5.5 M

Covid

Check 4D Molecular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 4D Molecular's main balance sheet or income statement drivers, such as Net Interest Income of 9.6 M, Interest Income of 9.6 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 36.34, Dividend Yield of 0.0 or PTB Ratio of 2.7. FDMT financial statements analysis is a perfect complement when working with 4D Molecular Valuation or Volatility modules.

Check out the analysis of 4D Molecular Correlation against competitors.

Latest 4D Molecular's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of 4D Molecular Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of 4D Molecular Therapeutics minus its cost of goods sold. It is profit before 4D Molecular operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. 4D Molecular's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (77.12 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

FDMT Gross Profit Regression Statistics

	Arithmetic Mean	(9,231,223)
	Geometric Mean	11,383,344
	Coefficient Of Variation	(332.42)
	Mean Deviation	24,421,394
	Median	5,790,000
	Standard Deviation	30,686,288
	Sample Variance	941.6T
	Range	94.4M
	R-Value	(0.63)
	Mean Square Error	613.2T
	R-Squared	0.40
	Significance	0.01
	Slope	(4,314,477)
	Total Sum of Squares	13183.1T

FDMT Gross Profit History

	2024	-72.6 M
	2023	-76.4 M
	2022	3.1 M
	2021	18 M
	2020	-39.4 M
	2019	-31.7 M
	2018	14.1 M

Other Fundumenentals of 4D Molecular Therapeutics

Gross Profit Margin

4D Molecular Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.23	0.96	-0.56	-0.98	-0.84	0.93	0.31	0.42	0.98	1.0	0.99	0.8	0.97	0.86	0.97	0.82	0.84
Total Stockholder Equity	0.23		0.28	-0.13	-0.29	-0.36	-0.01	0.36	-0.39	0.22	0.26	0.31	0.36	0.31	0.12	0.34	0.2	0.12
Net Tangible Assets	0.96	0.28		-0.64	-0.97	-0.86	0.88	0.19	0.34	0.97	0.96	0.95	0.81	0.95	0.88	0.96	0.82	0.84
Current Deferred Revenue	-0.56	-0.13	-0.64		0.51	0.85	-0.64	0.26	-0.06	-0.59	-0.52	-0.52	-0.78	-0.64	-0.85	-0.66	-0.91	-0.9
Net Debt	-0.98	-0.29	-0.97	0.51		0.82	-0.89	-0.36	-0.41	-0.95	-0.98	-0.97	-0.79	-0.92	-0.83	-0.93	-0.75	-0.77
Retained Earnings	-0.84	-0.36	-0.86	0.85	0.82		-0.83	-0.2	-0.09	-0.82	-0.82	-0.83	-0.98	-0.89	-0.92	-0.91	-0.95	-0.93
Accounts Payable	0.93	-0.01	0.88	-0.64	-0.89	-0.83		0.11	0.59	0.89	0.91	0.87	0.79	0.87	0.93	0.87	0.86	0.9
Net Receivables	0.31	0.36	0.19	0.26	-0.36	-0.2	0.11		-0.26	0.19	0.35	0.42	0.3	0.27	-0.05	0.27	-0.03	-0.06
Total Liab	0.42	-0.39	0.34	-0.06	-0.41	-0.09	0.59	-0.26		0.37	0.41	0.31	0.02	0.23	0.43	0.22	0.22	0.32
Net Invested Capital	0.98	0.22	0.97	-0.59	-0.95	-0.82	0.89	0.19	0.37		0.97	0.97	0.75	0.98	0.84	0.97	0.81	0.84
Total Current Assets	1.0	0.26	0.96	-0.52	-0.98	-0.82	0.91	0.35	0.41	0.97		0.99	0.78	0.96	0.83	0.96	0.78	0.81
Net Working Capital	0.99	0.31	0.95	-0.52	-0.97	-0.83	0.87	0.42	0.31	0.97	0.99		0.8	0.97	0.8	0.97	0.78	0.79
Short Term Debt	0.8	0.36	0.81	-0.78	-0.79	-0.98	0.79	0.3	0.02	0.75	0.78	0.8		0.85	0.87	0.87	0.89	0.87
Common Stock	0.97	0.31	0.95	-0.64	-0.92	-0.89	0.87	0.27	0.23	0.98	0.96	0.97	0.85		0.85	1.0	0.87	0.87
Property Plant Equipment	0.86	0.12	0.88	-0.85	-0.83	-0.92	0.93	-0.05	0.43	0.84	0.83	0.8	0.87	0.85		0.86	0.94	0.97
Capital Stock	0.97	0.34	0.96	-0.66	-0.93	-0.91	0.87	0.27	0.22	0.97	0.96	0.97	0.87	1.0	0.86		0.88	0.88
Capital Surpluse	0.82	0.2	0.82	-0.91	-0.75	-0.95	0.86	-0.03	0.22	0.81	0.78	0.78	0.89	0.87	0.94	0.88		0.99
Deferred Long Term Liab	0.84	0.12	0.84	-0.9	-0.77	-0.93	0.9	-0.06	0.32	0.84	0.81	0.79	0.87	0.87	0.97	0.88	0.99

Click cells to compare fundamentals

About 4D Molecular Financial Statements

4D Molecular shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although 4D Molecular investors may analyze each financial statement separately, they are all interrelated. The changes in 4D Molecular's assets and liabilities, for example, are also reflected in the revenues and expenses on on 4D Molecular's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	-76.4 M	-72.6 M
Gross Profit Margin	(3.69)	(3.87)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC